What is the first line of treatment for metastatic melanoma

According to the most recent NCCN Guidelines for Cutaneous Melanoma, the first-line treatment approach depends primarily on two key factors:

1. The patient's BRAF mutation status (whether the melanoma has a BRAF V600 mutation)
2. The extent and location of metastases

For BRAF-mutated melanoma, the NCCN Guidelines recommend two primary first-line options:

• BRAF/MEK inhibitor combination therapy (such as dabrafenib/trametinib or vemurafenib/cobimetinib)
• Immunotherapy with PD-1 inhibitors (pembrolizumab or nivolumab) either alone or in combination with ipilimumab

For BRAF wild-type melanoma (no mutation), the American Society of Clinical Oncology (ASCO) Guidelines strongly recommend:

• Anti-PD-1 immunotherapy as the preferred first-line treatment
• Either single-agent PD-1 inhibitor or combination immunotherapy with nivolumab plus ipilimumab, depending on individual patient factors

The National Cancer Institute (NCI) notes that the choice between these options should be individualized based on:

• Patient's overall health status
• Rate of disease progression
• Presence of symptoms
• Patient preferences regarding side effect profiles

It's crucial to emphasize that these treatment decisions should always be made in consultation with your oncology team, as they can take into account your specific situation and help determine the most appropriate first-line therapy for your case.